Gilead Sciences Inc., of Foster City, Calif., said it submitted a new drug application to Japan's Pharmaceutical and Medical Devices Agency for approval of sofosbuvir, a once-daily nucleotide analogue polymerase inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection.